Pablo E. Vivas‐Mejía

4.1k total citations
66 papers, 2.3k citations indexed

About

Pablo E. Vivas‐Mejía is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Pablo E. Vivas‐Mejía has authored 66 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 24 papers in Cancer Research and 11 papers in Oncology. Recurrent topics in Pablo E. Vivas‐Mejía's work include MicroRNA in disease regulation (17 papers), Circular RNAs in diseases (13 papers) and RNA Interference and Gene Delivery (11 papers). Pablo E. Vivas‐Mejía is often cited by papers focused on MicroRNA in disease regulation (17 papers), Circular RNAs in diseases (13 papers) and RNA Interference and Gene Delivery (11 papers). Pablo E. Vivas‐Mejía collaborates with scholars based in Puerto Rico, United States and Mexico. Pablo E. Vivas‐Mejía's co-authors include Anil K. Sood, Gabriel Lopez‐Berestein, Fatma Valiyeva, Mónica F. Díaz, Ileabett M. Echevarría-Vargas, Ginette S. Santiago-Sánchez, Lingegowda S. Mangala, Rebecca L. Stone, Menashe Bar‐Eli and Nicholas B. Jennings and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Pablo E. Vivas‐Mejía

65 papers receiving 2.2k citations

Peers

Pablo E. Vivas‐Mejía

ONCOL

IMMUN

PRM

Yuh-Lih Chang Taiwan

Whitney A. Spannuth United States

Man Yu Canada

Mian M.K. Shahzad United States

Nicoletta Filigheddu Italy

Carsten Hagemann Germany

Liz Y. Han United States

Yaping Tu United States

Ulf D. Kahlert Germany

David M. Gershenson United States

Yuh-Lih Chang Taiwan

Pablo E. Vivas‐Mejía

1.4k ×1.0

462 ×0.7

568 ×1.3

ONCOL

170 ×0.8

IMMUN

171 ×0.8

PRM

Citations per year, relative to Pablo E. Vivas‐Mejía Pablo E. Vivas‐Mejía (= 1×) peers Yuh-Lih Chang

Countries citing papers authored by Pablo E. Vivas‐Mejía

Since Specialization

Citations

This map shows the geographic impact of Pablo E. Vivas‐Mejía's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo E. Vivas‐Mejía with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo E. Vivas‐Mejía more than expected).

Fields of papers citing papers by Pablo E. Vivas‐Mejía

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo E. Vivas‐Mejía. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo E. Vivas‐Mejía. The network helps show where Pablo E. Vivas‐Mejía may publish in the future.

Co-authorship network of co-authors of Pablo E. Vivas‐Mejía

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo E. Vivas‐Mejía. A scholar is included among the top collaborators of Pablo E. Vivas‐Mejía based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo E. Vivas‐Mejía. Pablo E. Vivas‐Mejía is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rivera, Mariela, et al.. (2025). Upregulation of MMP3 Promotes Cisplatin Resistance in Ovarian Cancer. International Journal of Molecular Sciences. 26(9). 4012–4012. 1 indexed citations

Rivera, Mariela, et al.. (2025). Synthesis and Biological Evaluation of Herceptin-Conjugated Liposomes Loaded with Lipocalin-2 siRNA for the Treatment of Inflammatory Breast Cancer. Pharmaceuticals. 18(7). 1053–1053. 1 indexed citations

Pérez, Olivier, et al.. (2024). Effect of Cyclodextrins Formulated in Liposomes and Gold and Selenium Nanoparticles on siRNA Stability in Cell Culture Medium. Pharmaceuticals. 17(10). 1344–1344. 1 indexed citations

Vivas‐Mejía, Pablo E., et al.. (2022). A Fresh Look at the Potential of Cyclodextrins for Improving the Delivery of siRNA Encapsulated in Liposome Nanocarriers. ACS Omega. 7(4). 3731–3737. 7 indexed citations

Vivas‐Mejía, Pablo E., et al.. (2022). Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells. International Journal of Molecular Sciences. 23(23). 14742–14742. 5 indexed citations

Rivera, Mariela, et al.. (2022). Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences. 23(14). 7737–7737. 13 indexed citations

Santiago-Sánchez, Ginette S., Rohit Sharma, Abiel Roche-Lima, et al.. (2022). Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells. International Journal of Molecular Sciences. 23(1). 535–535. 7 indexed citations

Santiago-Sánchez, Ginette S., Eliud Hernandez O'Farril, Fatma Valiyeva, et al.. (2021). Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors. International Journal of Molecular Sciences. 22(16). 8581–8581. 15 indexed citations

Villodre, Emilly S., Xiaoding Hu, Richard Larson, et al.. (2021). Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Molecular Oncology. 15(10). 2752–2765. 27 indexed citations

10.

Santiago-Sánchez, Ginette S., et al.. (2020). Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer. International Journal of Molecular Sciences. 21(12). 4365–4365. 109 indexed citations

11.

Soto, Daniel E., et al.. (2020). Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer. Cancers. 12(4). 880–880. 15 indexed citations

12.

Valiyeva, Fatma, et al.. (2018). Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression. Cancers. 10(10). 382–382. 22 indexed citations

13.

Vivas‐Mejía, Pablo E., et al.. (2016). Anticancer Effect of Moringa oleifera Leaf Extract in Human Cancer Cell Lines. Journal of health disparities research and practice. 9(5). 102. 12 indexed citations

14.

Armaiz-Peña, Guillermo N., Lingegowda S. Mangala, Fatma Valiyeva, et al.. (2015). Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Molecular Cancer Therapeutics. 14(10). 2260–2269. 94 indexed citations

15.

Wen, Yunfei, Whitney A. Spannuth Graybill, Rebecca A. Previs, et al.. (2014). Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. Clinical Cancer Research. 21(2). 448–459. 53 indexed citations

16.

Courtney, Colleen M., et al.. (2013). cis-Antisense RNA and Transcriptional Interference: Coupled Layers of Gene Regulation. 1(1). 4 indexed citations

17.

Vivas‐Mejía, Pablo E., Cristian Rodriguez‐Aguayo, Hee‐Dong Han, et al.. (2011). Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer. Clinical Cancer Research. 17(11). 3716–3726. 58 indexed citations

18.

Spannuth, Whitney A., Lingegowda S. Mangala, Rebecca L. Stone, et al.. (2010). Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma. Molecular Cancer Therapeutics. 9(8). 2377–2388. 33 indexed citations

19.

Pan, Xue, Thiruvengadam Arumugam, Tameyoshi Yamamoto, et al.. (2008). Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells. Clinical Cancer Research. 14(24). 8143–8151. 105 indexed citations

20.

Mangala, Lingegowda S., Jansina Y. Fok, Yvonne G. Lin, et al.. (2008). Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma. Cancer Research. 68(14). 5849–5858. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact